Octave Specialty Group (OSG) Q1 2026 earnings review
Core Distribution Engine Roars, But Legacy Run-Off Haunts the Bottom Line
Octave Specialty Group's Q1 2026 results show a company in two distinct phases. The Insurance Distribution segment is Accelerating wildly, driving a 66% YoY surge in total revenue to $104.2M, fueled by the ArmadaCare acquisition and a staggering 41.8% organic growth rate. This pushed Adjusted EBITDA to a record $20.1M. However, the Everspan (Specialty P&C) segment suffered a Reversing trend in profitability, posting a disastrous 149.7% combined ratio due to legal settlements from a run-off program. The core growth thesis is fully intact, but dirty legacy accounting continues to drag GAAP net income into the red.
🐂 Bull Case
Insurance Distribution organic growth accelerated to 41.8%, while Adjusted EBITDA margins for the segment exploded to 32.3%. The MGA incubation strategy is clearly scaling.
The first full quarter with ArmadaCare drastically shifted the business mix toward high-margin, recurring Accident & Health (A&H) revenue, insulating Octave from traditional P&C volatility.
🐻 Bear Case
A 149.7% combined ratio in the Specialty P&C segment highlights the lingering risks of run-off programs. A single litigation settlement completely wiped out underwriting profitability.
Despite boasting $20.1M in Adjusted EBITDA, actual Net Income to shareholders remains negative (-$6.9M). The gap is bridged by massive amortization and restructuring costs that raise questions about earnings quality.
⚖️ Verdict: 🟢
Bullish. The 149.7% combined ratio at Everspan is ugly, but it's tied to a run-off program. The 41.8% organic growth and 32% margins in the core Insurance Distribution segment prove that the multi-year pivot away from the Ambac legacy is finally generating massive cash flow.
Key Themes
Insurance Distribution Firing on All Cylinders
The core engine of Octave's growth is Accelerating. Insurance Distribution revenue grew 92% YoY to $78.5M. Crucially, this wasn't just M&A—organic revenue growth hit 41.8%. The segment's Adjusted EBITDA more than tripled to $25.3M, expanding margins from 17.3% a year ago to 32.3%. The de novo MGA incubation strategy is hitting its stride.
ArmadaCare Propels the A&H Shift
The Q4 2025 acquisition of ArmadaCare is bearing fruit. Octave is leaning heavily into the Accident & Health market, capitalizing on seasonal Q1 strength. This provides a high-margin (>40%), recurring revenue stream that acts as a vital counterbalance to standard P&C cycle volatility.
Hammurabi AI Platform Deployment
Octave's proprietary AI platform, 'Hammurabi,' is shifting from concept to execution. Actively deployed in the medical stop-loss business, it provides near-instant risk prediction and pricing accuracy. This is an Accelerating technological moat that directly improves risk selection efficiency in a core product line.
Everspan Run-off Headaches Torpedo Underwriting
The Specialty P&C segment (Everspan) suffered a severe Reversing trend in underwriting profitability. The combined ratio exploded to 149.7% (from 102.1% in 25Q1). Management attributed this directly to a $7.9M hit ($2.1M losses, $5.8M legal) to settle potential litigation on a run-off program. While active programs ran at a 57% loss ratio, the ghosts of past underwriting continue to drain capital.
The GAAP vs. Non-GAAP Contradiction
Management heavily promoted a record $20.1M in Adjusted EBITDA to shareholders, yet GAAP Net Income remained mired in the red at -$6.9M. The bridge between the two is built on massive adjustments: $11.6M in intangible amortization, $4.6M in equity comp, and $8.0M in 'other non-operating losses.' If a company must consistently adjust away $25M+ in costs every quarter, investors must question the true underlying cash generation of the M&A roll-up strategy.
Macro Softening in P&C Pricing
While Octave's top-line is surging via acquisitions and MGA launches, the broader macro environment remains Stable-to-Decelerating. Management previously flagged entering a 'softening P&C market cycle' with 5% to 10% rate reductions in some non-cat property programs. If organic growth falters, this pricing pressure will immediately squeeze Everspan's active program margins.
Other KPIs
Accelerating. Up a massive 80% YoY. This is a stark reversal from 2025, where management deliberately shrank the book by non-renewing assumed programs. It indicates Everspan is returning to a growth posture, making the clean-up of legacy run-off programs even more critical to avoid further margin dilution.
Stable. Corporate overhead improved from a $10.0M loss in 25Q1 down to $6.9M. This demonstrates that management's previously announced cost reduction initiatives (including lease terminations and post-Ambac restructurings) are flowing through to the bottom line.
Guidance
Stable. Management noted that despite the blowout 149.7% combined ratio in Q1, the active programs are running at a 57% loss ratio, 'right in line with current accident year performance.' If the run-off noise stops, Everspan's underlying profitability should rebound sharply.
Accelerating. Based on prior quarter guidance, Everspan is targeting $410M in GWP for the full year. With $103.7M achieved in Q1 (+19% YoY), they are perfectly on pace to hit this target, marking an end to the 2025 premium contraction phase.
Key Questions
Quantifying Remaining Run-Off Exposure
The $7.9M litigation and loss hit on the run-off program derailed Everspan's profitability this quarter. What is the total maximum remaining exposure to these run-off programs, and when can investors expect a completely clean quarter free of legacy adverse development?
GAAP Profitability Timeline
Adjusted EBITDA is scaling beautifully, but GAAP Net Income continues to be dragged down by amortization and restructuring costs. At what point in the M&A and MGA incubation cycle do you expect the business to generate consistent, unadjusted GAAP Net Income?
Organic Growth Sustainability
Insurance Distribution organic growth hit an incredible 41.8%. Given the softening macro P&C pricing environment, how much of this growth is driven by sheer volume versus rate, and is a 40%+ organic rate sustainable for the rest of FY26?